Role of neoadjuvant chemotherapy in rectal cancer: Interpretation of the EXPERT study [1]

Journal of Clinical Oncology

Volumn 24, Issue 28, 2006, Pages 4664-4665

  Glynne Jones, Rob ^a   Sebag Montefiore, David ^b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b United Kingdom   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

ADJUVANT THERAPY; ADVANCED CANCER; ANUS CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LAPAROTOMY; LETTER; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METHODOLOGY; MORTALITY; NOTE; RECTUM TUMOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33750586461     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.9491     Document Type: Letter

References (9)

1. Chau I, Brown G, Cunningham D, et al: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668-674, 2006
2. Rodel C, Grabenbauer GG, Papadopoulos T, et al: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098-3104, 2003
3. Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, et al: Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350-1357, 2005
4. Glynne-Jones R, Sebag-Montefiore D, Samuel L, et al: Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). J Clin Oncol 23:252s, 2005 (abstr 3527)
5. Sebag-Montefiore D, Brown G, Rutten H, et al: An international phase II study of capecitabine, oxaliplatin, radiotherapy and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Interim results. Eur J Cancer 3: 170, 2005 (abstr 608)
6. Brada AM, Tannock IF: Scheduling of radiation and chemotherapy for limited stage small cell lung cancer: Repopulation as a cause of treatment failure. J Clin Oncol 24:1020-1022, 2006
7. Ajani JA, Winter KA, Gunderson LL, et al: Intergroup RTOG 98-11: A phase III randomized study of (5FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol 24:180s, 2006 (abstr 4009)
8. Mawdsley S, Glynne-Jones R, Grainger J, et al: Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 63:745-752, 2005
9. Sebag-Montefiore D, Hingorani M, Cooper R, et al: Circumferential resection margin status predicts outcome after pre-operative chemoradiation for locally advanced rectal cancer. Proceedings of J Clin Oncol GI Symposium 2005 (abstr 193)